As scientists, we are challenged to discover better treatments and cure for cancer patients.
At In Vitro Technologies, we offer to participate in your cancer research journey by providing authenticated models, high quality reagents and newer technologies to answer previously unanswered questions.
It is extensively documented that cancer is an extremely complicated disease and consists of more than 100 distinct diseases that manifest in about 200 cell types with diverse mutational etiologies. This complexity is compounded by the fact that a single disease phenotype can result from multiple genotypes and a single tumor sample could have over a hundred different mutations.
As such, the goal to eradicate cancer is dependent on a deeper understanding of the disease. Weinberg and Hanahan (2011) Hallmarks of Cancer in their seminal paper organised the complexities of cancer into key underlying principles since most if not all human cancers share a small number of molecular, biochemical, and cellular traits. Exploring these concepts will support the development of new and improved cancer therapies.
Much of what we know about the hallmarks of cancer has come through in vitro cell biology research. Cell-based assays are positioned between reductionist biochemical assays and whole organism in vivo experimentation, and are an indispensable tool in both basic and translational cancer research. At In Vitro Technologies we are committed to help you accelerate your cancer research towards positive clinical outcomes.
Together with our partners, ATCC, Biotechne and Agilent bring you the most cited and recognised solutions to Accelerate Cancer Research in the ANZ market, towards improved understanding of the disease that will facilitate better therapeutic approaches.
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models, including organoids and conditionally reprogrammed cells (CRCs). ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
ATCC's short documentary film "Next-Generation Biological Models: Revolutionising Cancer Research" explores the Human Cancer Models Initiative (HCMI), a groundbreaking international research collaboration to transform cancer research and therapeutic development.